Intelligent Bio Solutions (INBS) has shared an announcement.
Intelligent Bio Solutions Inc. has announced the successful completion of the in-clinic phase of its pharmacokinetic study, marking a significant step toward seeking regulatory approval through the 510(k) pathway. This milestone is critical for the company’s clinical study plan and could be a positive indicator for investors tracking the company’s progress in bringing its products to market.
Learn more about INBS stock on TipRanks’ Stock Analysis page.
